The Francis Crick Institute
cells-11-01334-v3 (2).pdf (3.32 MB)

Research status of the orphan G protein coupled receptor 158 and future perspectives.

Download (3.32 MB)
journal contribution
posted on 2022-04-29, 08:12 authored by Xianan Fu, Shoupeng Wei, Tao Wang, Hengxin Fan, Ying Zhang, Clive Da Costa, Sebastian Brandner, Guang Yang, Yihang Pan, Yulong He, Ningning Li
G-protein-coupled receptors (GPCRs) remain one of the most successful targets for therapeutic drugs approved by the US Food and Drug Administration (FDA). Many novel orphan GPCRs have been identified by human genome sequencing and considered as putative targets for refractory diseases. Of note, a series of studies have been carried out involving GPCR 158 (or GPR158) since its identification in 2005, predominantly focusing on the characterization of its roles in the progression of cancer and mental illness. However, advances towards an in-depth understanding of the biological mechanism(s) involved for clinical application of GPR158 are lacking. In this paper, we clarify the origin of the GPR158 evolution in different species and summarize the relationship between GPR158 and different diseases towards potential drug target identification, through an analysis of the sequences and substructures of GPR158. Further, we discuss how recent studies set about unraveling the fundamental features and principles, followed by future perspectives and thoughts, which may lead to prospective therapies involving GPR158.


Crick (Grant ID: 10018, Grant title: STP BRF)


Usage metrics

    The Francis Crick Institute



    Ref. manager